GlobalData’s clinical trials dashboard is powered by the Pharma Intelligence Center, which boasts a highly comprehensive source of Clinical Trials collated from numerous government, non-government ...

The US Pharmacopeia (USP) has proposed a revision to General Chapter <660> Container—Glass, which provides specifications for ...

Public markets are showing early signs of reopening, as Q4 2025 saw a 157% increase in IPO deal volume compared to Q4 2024.

AbbVie’s lost exclusivity for Humira is offset by immunology and neurology sales, diversified by its emerging oncology ...

Johnson & Johnson’s (J&J) Caplyta (lumateperone) plus antidepressants nearly doubled the likelihood of remission after six ...

Agenus has completed a $141m strategic collaboration with Zydus Lifesciences to accelerate the global development and ...

The funding aims to encourage innovation in Europe amid concerns that innovation across the continent is lagging behind China ...

Novo Nordisk is positioning itself as a long‑term leader across multiple obesity segments rather than relying on a single ...

Eli Lilly highlighted 2025 as the rollout year for obesity drugs, with Mounjaro at the forefront of its weight-loss portfolio ...

Clinical and commercial quality controls are eased as the FDA looks to expedite therapy approvals in areas of unmet need.

InterAx Biotech has entered into a strategic research collaboration and licensing agreement with Alveus Therapeutics to ...

Jazz Pharmaceuticals has sold a priority review voucher (PRV) for $200m, suggesting the uptick in market prices for the ...